Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Abstract

Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov number, NCT02574455; EudraCT number, 2017-003019-21.).

Keywords

Affiliated Institutions

• KU Leuven BE
• Vall d'Hebron Institute of Oncology
• Columbia University Irving Medical Center US
• International Breast Cancer Study Group CH
• UCSF Helen Diller Family Comprehensive Cancer Center US
• University of California, Los Angeles US
• Texas Oncology US
• Université Libre de Bruxelles BE
• Institut Jules Bordet BE
• Northside Hospital US
• Georgetown Lombardi Comprehensive Cancer Center
• Magee-Womens Hospital US
• Centre Eugène Marquis FR
• Rocky Mountain Cancer Centers US
• Florida Cancer Specialists & Research Institute US
• University of North Carolina at Chapel Hill US
• UPMC Hillman Cancer Center US
• Massachusetts General Hospital US
• University of Pittsburgh Medical Center US
• A.P. Giannini Foundation US
• Baylor University Medical Center US
• Institut Curie FR
• Jewish General Hospital CA
• Krankenhaus Bethanien DE
• The Ohio State University Wexner Medical Center US
• Hebron University PS
• Queen Mary University of London GB
• UCLA Jonsson Comprehensive Cancer Center
• Dana-Farber Cancer Institute US
• UNC Lineberger Comprehensive Cancer Center
• Cancer Institute (WIA) IN
• Institut Claudius Regaud FR
• University of California, San Francisco US
• Memorial Sloan Kettering Cancer Center US
• Breast Center CH

Related Publications